MX2023000948A - Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). - Google Patents

Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).

Info

Publication number
MX2023000948A
MX2023000948A MX2023000948A MX2023000948A MX2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A
Authority
MX
Mexico
Prior art keywords
cytokine fusion
cytokine
dual
fusion proteins
disorders
Prior art date
Application number
MX2023000948A
Other languages
English (en)
Spanish (es)
Inventor
John Mumm
Original Assignee
Deka Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deka Biosciences Inc filed Critical Deka Biosciences Inc
Publication of MX2023000948A publication Critical patent/MX2023000948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023000948A 2020-07-20 2020-12-02 Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). MX2023000948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063054208P 2020-07-20 2020-07-20
PCT/US2020/062907 WO2022019945A1 (en) 2020-07-20 2020-12-02 Dual cytokine fusion proteins comprising il-10

Publications (1)

Publication Number Publication Date
MX2023000948A true MX2023000948A (es) 2023-04-14

Family

ID=79291996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000948A MX2023000948A (es) 2020-07-20 2020-12-02 Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).

Country Status (11)

Country Link
US (19) US11292822B2 (https=)
EP (1) EP4181957A4 (https=)
JP (1) JP2023534847A (https=)
KR (1) KR20230096959A (https=)
CN (1) CN116322785A (https=)
AU (1) AU2020459746A1 (https=)
BR (1) BR112023001187A2 (https=)
CA (1) CA3186753A1 (https=)
IL (1) IL300062A (https=)
MX (1) MX2023000948A (https=)
WO (1) WO2022019945A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
CN118900697A (zh) * 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法
KR20250078792A (ko) * 2023-11-24 2025-06-04 주식회사 메드팩토 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
EA200802289A1 (ru) 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2009056268A1 (en) 2007-10-30 2009-05-07 Philogen S.P.A. An antigen associated with rheumatoid arthritis
NZ592420A (en) 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
US9249225B2 (en) * 2010-05-26 2016-02-02 Regents Of The University Of Minnesota Single chain variable fragment anti-CD133 antibodies and uses thereof
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
KR102277469B1 (ko) 2011-12-12 2021-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
CN104245722A (zh) 2012-02-29 2014-12-24 Ambrx公司 白细胞介素-10多肽结合物和其用途
CA2876285A1 (en) * 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
RU2612878C2 (ru) * 2012-10-03 2017-03-13 Филоджен С.П.А. Антигены, ассоциированные с воспалительным заболеванием кишечника
KR20160043927A (ko) 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR101811050B1 (ko) 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2017091611A1 (en) 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
CA3044556C (en) 2016-04-12 2020-11-17 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018156791A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
EP3625253A4 (en) * 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP2022524018A (ja) 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
US20210214782A1 (en) 2020-01-09 2021-07-15 Deka Biosciences, Inc. Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment
AU2021257439A1 (en) 2020-04-13 2022-12-15 University Health Network Methods for treating cytokine release syndrome
CA3186753A1 (en) * 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CA3215528A1 (en) 2021-05-11 2022-11-17 Salvatore Albani Chimeric antigen receptors and modified cells comprising the same
JP2024546938A (ja) 2021-12-13 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
JP2024546999A (ja) 2021-12-16 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
CN118900697A (zh) 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法

Also Published As

Publication number Publication date
US11608368B2 (en) 2023-03-21
US12110317B2 (en) 2024-10-08
US11618775B2 (en) 2023-04-04
US20240067688A1 (en) 2024-02-29
US11629178B2 (en) 2023-04-18
US20220275040A1 (en) 2022-09-01
US12116393B2 (en) 2024-10-15
AU2020459746A1 (en) 2023-03-16
US12116391B2 (en) 2024-10-15
BR112023001187A2 (pt) 2023-04-04
CA3186753A1 (en) 2022-01-27
US20220281935A1 (en) 2022-09-08
US12263358B2 (en) 2025-04-01
CN116322785A (zh) 2023-06-23
US20220267397A1 (en) 2022-08-25
US20240059748A1 (en) 2024-02-22
US20250135241A1 (en) 2025-05-01
US20240076337A1 (en) 2024-03-07
US12268903B2 (en) 2025-04-08
US20220340631A1 (en) 2022-10-27
US20220017587A1 (en) 2022-01-20
IL300062A (en) 2023-03-01
US12116390B2 (en) 2024-10-15
US11572397B2 (en) 2023-02-07
WO2022019945A1 (en) 2022-01-27
US20240059749A1 (en) 2024-02-22
US11613563B2 (en) 2023-03-28
US20240076339A1 (en) 2024-03-07
US20240059750A1 (en) 2024-02-22
US12121755B2 (en) 2024-10-22
US12116392B2 (en) 2024-10-15
US20220380428A1 (en) 2022-12-01
US20220275039A1 (en) 2022-09-01
US12145007B2 (en) 2024-11-19
US20240076335A1 (en) 2024-03-07
JP2023534847A (ja) 2023-08-14
US11292822B2 (en) 2022-04-05
US20220380427A1 (en) 2022-12-01
US20240067687A1 (en) 2024-02-29
US20240076336A1 (en) 2024-03-07
US12006346B2 (en) 2024-06-11
KR20230096959A (ko) 2023-06-30
US12116389B2 (en) 2024-10-15
US20240076338A1 (en) 2024-03-07
EP4181957A4 (en) 2024-08-07
EP4181957A1 (en) 2023-05-24
US12122814B2 (en) 2024-10-22

Similar Documents

Publication Publication Date Title
MX2023000948A (es) Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
MX2024007270A (es) Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades.
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
WO2023115033A3 (en) Dual cytokine fusions comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
PH12023552763A1 (en) Agonistic anti-il-2r antibodies and methods of use
MY208638A (en) Anti-steap1 antigen-binding protein
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
UA130540C2 (uk) Композиція антитіла b7-h4
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
WO2022038417A3 (en) Modified il-18 polypeptides and uses thereof
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
WO2021262880A3 (en) Anti-pd-1 antibodies and fusion proteins
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
AU2018281871A1 (en) Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins